Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
WALTHAM, Mass., March 02, 2017 -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended December 31, 2016, on March 16, 2017 before the market opens.
Histogenics’ management will host a conference call on Thursday, March 16, 2017 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics’ remarks. To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “56826793” five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the presentation.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
